.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,461,643

« Back to Dashboard

Details for Patent: 6,461,643

Title: Oral drug delivery compositions and methods
Abstract:The present invention relates to an oral drug delivery system, and in particular to modified amino acids and modified amino acid derivatives for use as a delivery system of sensitive agents such as bioactive peptides. The modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form durg containing microspheres. These mixtures are suitable for oral administration of biologically active agents to animals. Methods for the preparation of such amino acids are also disclosed.
Inventor(s): Milstein; Sam J. (Larchmont, NY), Barantsevitch; Evgueni N. (New Rochelle, NY), Sarubbi; Donald J. (Bronxville, NY), Leone-Bay; Andrea (Ridgefield, CT), Paton; Duncan R. (Purdys, NY)
Assignee: Emisphere Technologies, Inc. (Tarrytown, NY)
Filing Date:May 21, 2001
Application Number:09/862,063
Claims:1. A composition comprising: (A) at least one biologically-active agent; and (B) a compound having the formula:

wherein: Ar is a substituted or unsubstituted phenyl or naphthyl; ##STR10## ##STR11## R.sup.3 is C.sub.1 to C.sub.24 alkyl, C.sub.1 to C.sub.24 alkenyl, phenyl, naphthyl, (C.sub.1 to C.sub.10 alkyl) phenyl, (C.sub.1 to C.sub.10 alkenyl) phenyl, (C.sub.1 to C.sub.10 alkyl) naphthyl, (C.sub.1 to C.sub.10 alkenyl) naphthyl, phenyl (C.sub.1 to C.sub.10 alkyl), phenyl (C.sub.1 to C.sub.10 alkenyl), naphthyl (C.sub.1 to C.sub.10 alkyl), and naphthyl (C.sub.1 to C.sub.10 alkenyl); R.sup.3 is optionally substituted with C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, C.sub.1 to C.sub.4 alkoxy, --OH, --SH, --CO.sub.2 R.sup.5, cycloalkyl, cycloalkenyl, heterocyclic, aryl, alkaryl, heteroaryl or heteroalkaryl or any combination thereof; R.sup.5 is hydrogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkenyl; R.sup.3 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof; and R.sup.4 is hydrogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkenyl; and n is from 1 to 5.

2. The composition according to claim 1, wherein Ar is substituted or unsubstituted phenyl; ##STR12## R.sup.3 is C.sub.1 to C.sub.24 alkyl, (C.sub.1 to C.sub.10 alkyl) phenyl, or phenyl (C.sub.1 to C.sub.10 alkyl); and n is equal to 1.

3. The composition according to claim 1, wherein said biologically-active agent is selected from the group consisting of a peptide, a polysaccharide, a mucopolysaccharide, a carbohydrate, a lipid, or any combination thereof.

4. The composition according to claim 1, wherein said biologically-active agent is a peptide.

5. The composition according to claim 1, wherein said biologically-active agent is a mucopolysaccharide.

6. The composition according to claim 1, wherein said biologically-active agent is a lipid.

7. The composition according to claim 1, wherein said biologically-active agent is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-I, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, or any combination thereof.

8. The composition according to claim 7, wherein said biologically-active agent is an interferon.

9. The composition according to claim 7, wherein said biologically-active agent is insulin.

10. The composition according to claim 7, wherein said biologically-active agent is human growth hormone.

11. The composition according to claim 7, wherein said biologically-active agent is heparin.

12. The composition according to claim 7, wherein said biologically-active agent is low molecular weight heparin.

13. The composition according to claim 7, wherein said biologically-active agent is calcitonin.

14. The composition according to claim 7, wherein said biologically-active agent is cromolyn sodium.

15. A dosage unit form comprising (A) a composition according to claim 1; and (B) (a) an excipient, (b) a diluent, (c) a disintegrant, (d) a lubricant, (e) a plasticizer, (f) a colorant, (e) a dosing vehicle, or (h) any combination thereof.

16. The dosage unit form according to claim 15, comprising a tablet, a capsule, or a liquid.

17. A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal the compositin as defined in claim 1.

18. A method for preparing a composition, said method comprising mixing: (A) at least one biologically-active agent; and (B) a compound having the formula:

wherein: Ar is a substituted or unsubstituted phenyl or naphthyl; ##STR13## ##STR14## R.sup.3 is C.sub.1 to C.sub.24 alkyl, C.sub.1 to C.sub.24 alkenyl, phenyl, naphthyl, (C.sub.1 to C.sub.10 alkyl) phenyl, (C.sub.1 to C.sub.10 alkenyl) phenyl, (C.sub.1 to C.sub.10 alkyl) naphthyl, (C.sub.1 to C.sub.10 alkenyl) naphthyl, phenyl (C.sub.1 to C.sub.10 alkyl), phenyl (C.sub.1 to C.sub.10 alkenyl), naphthyl (C.sub.1 to C.sub.10 alkyl), and naphthyl (C.sub.1 to C.sub.10 alkenyl); R.sup.3 is optionally substituted with C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, C.sub.1 to C.sub.4 alkoxy, --OH, --SH, --CO.sub.2 R.sup.5, cycloalkyl, cylcloalkenyl, heterocyclic, aryl, alkaryl, heteroaryl or heteroalkaryl or any combination thereof; R.sup.5 is hydrogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkenyl; R.sup.3 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof; R.sup.4 is hydrogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkenyl; and n is from 1 to 5.

19. A dosage unit form as defined in claim 15, wherein said biologically-active agent is selected from the group consisting of a peptide, a polysaccharide, a mucopolysaccharide, a carbohydrate, a lipid, a pesticide, or any combination thereof.

20. The dosage unit form as defined in claim 19, wherein the biologically-active agent is a mucopolysaccharide.

21. The dosage unit form as defined in claim 20, wherein the mucopolysaccharide is heparin.

22. The dosage unit form as defined in claim 20, wherein the mucopolysaccharide is low molecular weight heparin.

23. The dosage unit form as defined in claim 19, wherein the biologically-active agent is a peptide.

24. The dosage unit form as defined in claim 23, wherein said peptide is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenoctorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, and any combination thereof.

25. The dosage unit form as defined in claim 24, wherein the peptide is insulin.

26. The dosage unit form as defined in claim 24, wherein the peptide is interferon.

27. The dosage unit form as defined in claim 24, wherein the peptide is human growth hormone.

28. The dosage unit form as defined in claim 24, wherein the peptide is calcitonin.

29. The dosage unit form as defined in claim 24, wherein the peptide is an antigen.

30. The dosage unit form as defined in claim 15, wherein the biologically-active agent is cromolyn sodium.

31. The dosage unit form as defined in claim 19, comprising a tablet, a capsule, or a liquid.

32. The dosage unit form as defined in claim 31, wherein said dosing vehicle is selected from the group consisting of water, 1,2-propane diol, ethanol, and any combination thereof.

33. A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 19.

34. The method for administering as defined in claim 33, wherein the biologically-active agent is a mucopolysaccharide.

35. The method for administering as defined in claim 33, wherein the mucopolysaccharide is heparin.

36. The method for administering as defined in claim 33, wherein the mucopolysaccharide is low molecular weight heparin.

37. The method as defined in claim 33, wherein said biologically-active agent is a peptide.

38. The method as defined in claim 37, wherein said peptide is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone- releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, calcitonin, erythropoietin, atrial naturtic factor, an antigen, a monoclonal antibody, sommatostatin, adrenoctorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, and any combination thereof.

39. The method as defined in claim 37, wherein the peptide is insulin.

40. The method as defined in claim 37, wherein the peptide is interferon.

41. The method as defined in claim 37, wherein the peptide is growth hormone.

42. The method as defined in claim 37, wherein the peptide is calcitonin.

43. The method as defined in claim 37, wherein the peptide is an antigen.

44. The method as defined in claim 33, wherein the biologically-active agent is cromolyn sodium.

45. The composition of claim 7, wherein the biologically active-agent is an antigen.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc